BBIO News and Press, BridgeBio Pharma Inc. From 12/11/25

2025-12-11 05:06:16 ET from Bernstein issued a price target of $94.00 for BBIO on 2025-12-11 09:54:18. The adjusted price target was set to $94.00. At the time of the announcement, BBIO was trading at $72.7. The overall price target consensus is at $83.71 with high price...

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fires...

2025-11-23 07:04:57 ET Introduction BridgeBio (BBIO) has risen roughly 90% since I initiated coverage back in April of 2025. It quickly became the largest position in my portfolio and was the primary driver of my outperformance this year.... Read the full article on Seekin...

2025-11-10 20:21:32 ET BridgeBio Pharma, Inc. (BBIO) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk r...

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats ...

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the Amer...

2025-10-31 14:33:26 ET ... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts

2025-10-29 22:57:08 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript BridgeBio Pharma, Inc. 2025 Q3 - Results - Earnings Call Presentation BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in AD...

2025-10-29 22:56:25 ET BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript